Fresenius Acquires Remaining 45% of mAbxience
Fresenius has acquired the remaining 45% of its biopharmaceutical joint venture, mAbxience.
Story updates
05:05:52 AM UTC
SquawkNews
Fresenius: Acquiring mAbxience Stake for Up to EUR750M
05:27:56 AM UTC
SquawkNews
(05:04 GMT) *Fresenius Acquires Remaining 45% of mAbxience (05:05 GMT) *Fresenius: Acquiring mAbxience Stake for Up to EUR750M (05:06 GMT) *Fresenius: Taking Full Ownership of Its Biosimilars Platform With Acquisition (05:06 GMT) *Fresenius: Buying Stake for Insud Pharma and Invim Corporativo (05:2…